UNSPSC 51391902: Azepexole

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H15N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DGB112538O, chemically known as 4h-oxazolo(4,5-d)azepin-2-amine, 6-ethyl-5,6,7,8-tetrahydro-, dihydrochloride but generally known as azepexole, which bears US NIH Compound Identifier 2277. Azepexole most often comes in base and hydrochloride forms. European Medicines Agency schedules Azepexole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05651MIG.

UNSPSC 51391902 Azepexole, a Commodity code, sees minimal recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities tagged to this code do not reflect azepexole purchasing; instead, Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for naloxone and safe drug deactivation systems—1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs and pharmacy benefit management, a market-intelligence solicitation addressing contracting models and vendor capabilities rather than specific pharmaceutical commodities. Neither opportunity involves azepexole procurement, suggesting the code may carry mislabeled state and local activity or sees limited recent demand under its intended product classification.

Issuing bodies and geographic concentration cannot be reliably characterized from these two misaligned records. Seminole County represents a single Florida county health procurement; the Texas HHS Commission RFI addresses statewide pharmacy benefit strategy at the state department level. The Seminole County opportunity includes a two-year contract term with a one-year renewal option, quarterly delivery cadence, and requirements for drug-free workplace certification and E-Verify compliance, though budget amounts are not specified. The code shows no other recent state or local opportunities in the block, indicating either sparse activity or systematic tagging misalignment between the code and actual purchasing patterns. Firms evaluating this code should verify whether state and local procurement offices are actively soliciting azepexole under this classification or whether opportunities fall under different commodity codes.